This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar - Takeaways - MDSpire
Clinical Guidelines

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min

Share

  • 1

    POHERDY is the first biosimilar for pertuzumab in Europe.

  • 2

    NICE recommends rozanolixizumab for myasthenia gravis.

  • 3

    GX-BP1 shows 70% tumor inhibition in preclinical models.

  • 4

    Ecolab opened a new bioprocessing lab in Korea.

  • 5

    WuXi Biologics achieved GMP certification for bispecific antibodies in Korea.

Original Source(s)

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

  • May 5, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...